The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers
Open accessPublished version of a preprint
Abstract
UNLABELLED: Protein arginine methyltransferase 5 (PRMT5) has been implicated as a key modulator of lymphomagenesis. Whether PRMT5 has overt oncogenic function in the context of leukemia/lymphoma and whether it represents a therapeutic target remains to be established. We demonstrate that inactivation of PRMT5 inhibits colony-forming activity by multiple oncogenic drivers, including cyclin D1, c-MYC, NOTCH1, and MLL-AF9. Furthermore, we demonstrate that PRMT5 overexpression specifically cooperates with cyclin D1 to drive lymphomagenesis in a mouse model, revealing inherent neoplastic activity. Molecular analysis of lymphomas revealed that arginine methylation of p53 selectively suppresses expression of crucial proapoptotic and antiproliferative target genes, thereby sustaining tumor cell self-renewal and proliferation and bypassing the need for the acquisition of inactivating p53 mutations. Critically, analysis of human tumor specimens reveals a strong correlation between cyclin D1 overexpression and p53 methylation, supporting the biomedical relevance of this pathway. SIGNIFICANCE: We have identified and functionally validated a crucial role for PRMT5 for the inhibition of p53-dependent tumor suppression in response to oncogenic insults. The requisite role for PRMT5 in the context of multiple lymphoma/leukemia oncogenic drivers suggests a molecular rationale for therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of the enzymes targeted, particularly lysine and arginine methyltransferases, have non-histone substrates”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [182]
Experimental — accuracy not yet measuredIn the citing paper
“Moreover, certain cyclin D mutants or C-terminally truncated variants encoded by an alternatively spliced mRNA (D1b) that lacks the Thr-286 codon are retained in the nucleus during S phase and are proposed to confer a neo-oncogenic function that triggers DNA re-replication, aneuploidy, and tumorigenesis (59-61).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“The tumor suppressor properties of p53 have been linked to its function as a transcription factor that regulates the expression of target genes linked with cell cycle arrest, apoptosis, senescence and DNA repair (25, 26).”
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
An Oncogene-Induced DNA Damage Model for Cancer Development
Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851 · cited 1×
“p53 is the central regulator of cell fate following numerous stresses including genotoxic stress and oncogene activation (23, 24).”
InfluentialProtein Arginine Methylation in Mammals: Who, What, and Why
Bedford, M. T., & Clarke, S. G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.013 · Cited by 1,792 · cited 1×
“3 INTRODUCTION Arginine methylation is becoming increasingly appreciated as an important mechanism of post-transcriptional control (1).”
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 2×
“Data demonstrating that mutant p53 alleles frequently have neopmorphic activities and thus do not equate with p53 deletion support this conclusion (28).”
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · cited 2×
“The retention of wild-type p53 is generally associated with the loss of key effectors such as p19 ARF (p14 ARF in human cells) or with the overexpression of MDM2 (18, 40-42).”
Self-citationA novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Bedford, M. T., & Richard, S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.003 · Cited by 1,099 · cited 1×
“Proteins targeted by arginine methylation contribute to a variety of cellular processes including transcriptional regulation, chromatin regulation, RNA processing and DNA damage repair (2-4).”
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089 · cited 1×
“Cyclin D1, together with its binding partners cyclin dependent kinase 4 and 6 (CDK4/6), forms an active complex that promotes cell cycle progression by phosphorylating and inactivating the retinoblastoma protein (14).”
Sherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980
Cited by
Arginine Methylation: The Coming of Age
Blanc, R. S., & Richard, S. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.11.003 · Cited by 1,054
“This crosstalk between H4R3me2a and H3K9/14Ac was reported to be present in various biological processes from cell differentiation to the response to cocaine (Li et al., 2015c).”
BackgroundInfluentialTargeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
“More recent work revealed that cyclin D1-CDK4 can inactivate p53 through PRMT5-dependent p53 methylation, thereby permitting tumor progression while maintaining wild-type p53 [40, 102].”
BackgroundInfluentialSelf-citationp53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Metadata
- Authors
- Li, Y., Chitnis, N., Nakagawa, H., Kita, Y., Natsugoe, S., Yang, Y., Li, Z., Wasik, M., Klein-Szanto, A. J. P., Rustgi, A. K., & Diehl, J. A.
- Affiliations
- University of Pennsylvania (US)
- Abramson Cancer Center (US)
- Kagoshima University (JP)
- Medical University of South Carolina (US)
- 7Fox Chase Cancer Center, Philadelphia, Pennsylvania.
- Corresponding author
- Diehl, J. Alan
- ORCID
- Venue
- Cancer Discovery
- Published
- 2015-03-01
- Volume
- 5
- Issue
- 3
- Pages
- 288-303
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4355177
- OpenAlex
- W2137003359
- Cited by
- 143
- References
- 49
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 19 · 2021: 13 · 2020: 15 · 2019: 18 · 2018: 17 · 2017: 12 · 2016: 12 · 2015: 6
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P01CA098101, CA11360, R01CA093237)
- National Institute of Allergy and Infectious Diseases (R01AI070603)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK050306)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- PRMT5, protein arginine methyltransferase, lymphomagenesis, cyclin D1, c-Myc, Notch1, MLL-AF9, leukemia, lymphoma, tumor self-renewal, therapeutic target
- MeSH terms
- Animals, Arginine, Cell Transformation, Neoplastic, Enzyme Activation, Humans, Lymphoma, Methylation, Mutation, Oncogenes, Phosphorylation, Protein-Arginine N-Methyltransferases, Transcription Factors, Leukemia, T-Cell, Cluster Analysis, Tumor Suppressor Protein p53, Lymphoma, T-Cell, Apoptosis, Cyclin D1, Amino Acid Substitution, Gene Expression Profiling, Adaptor Proteins, Signal Transducing, Cyclin-Dependent Kinase 4, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-0625
- The paper
- Li, Y., Chitnis, N., Nakagawa, H., Kita, Y., Natsugoe, S., Yang, Y., Li, Z., Wasik, M., Klein-Szanto, A. J. P., Rustgi, A. K., & Diehl, J. A. (2015). PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-0625
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.